BUY MBP LIPOSOMAL DOXORUBICIN HYDROCHLORIDE PEGY PEGADRIA 50MG VIAL BEST PRICE ONLINE IN NIGERIA LAGOS ABUJA KANO AND PORTHARCOURT AT MYBIGPHARMACY.COM

Description

Dear friend, this medication requires a prescription or medical license before it can be delivered to you. kindly ensure that you provide us with a reliable contact information at checkout, mybigpharmacy team will be in touch with you to obtain required document before your order is confirmed thank you for trusting mybig pharmacy with your health. Medicine name: Pegylated liposomal doxorubicin hydrochloride
Common brand name: Doxil or Caelyx

I would like to explain your chemotherapy medicine called pegylated liposomal doxorubicin hydrochloride so you understand why pegylated liposomal doxorubicin hydrochloride has been prescribed, how pegylated liposomal doxorubicin hydrochloride works, how pegylated liposomal doxorubicin hydrochloride is given, and what to expect while receiving pegylated liposomal doxorubicin hydrochloride. This is detailed information, but it is important so you feel informed and supported during treatment.

Pegylated liposomal doxorubicin hydrochloride is a chemotherapy medicine used to treat certain cancers, including ovarian cancer, breast cancer, multiple myeloma, Kaposi sarcoma, and some other cancers. Pegylated liposomal doxorubicin hydrochloride contains the active drug doxorubicin, but it is packaged in a special way to improve safety and tolerability compared with standard doxorubicin.

Pegylated liposomal doxorubicin hydrochloride works by damaging the DNA of cancer cells. Cancer cells need to copy their DNA in order to grow and divide. Pegylated liposomal doxorubicin hydrochloride interferes with this process, causing cancer cells to stop growing and eventually die. The liposomal and pegylated coating allows pegylated liposomal doxorubicin hydrochloride to stay in the bloodstream longer and concentrate more in tumour tissue, while reducing exposure to healthy tissues.

Pegylated liposomal doxorubicin hydrochloride is given as an intravenous infusion through a drip into a vein. Pegylated liposomal doxorubicin hydrochloride is administered in a hospital or oncology day unit by trained healthcare professionals. The infusion is given slowly, especially the first time, to reduce the risk of infusion-related reactions. The dosing schedule of pegylated liposomal doxorubicin hydrochloride is usually once every few weeks, depending on your treatment plan.

During the infusion of pegylated liposomal doxorubicin hydrochloride, you will be closely monitored. Some people experience infusion-related reactions, particularly during the first dose. Symptoms may include flushing, shortness of breath, chest tightness, back pain, fever, chills, rash, or itching. If you feel unwell at any point during the infusion of pegylated liposomal doxorubicin hydrochloride, tell the nurse immediately. These reactions are usually manageable when identified early.

One of the key side effects of pegylated liposomal doxorubicin hydrochloride is its effect on the skin and mouth. Pegylated liposomal doxorubicin hydrochloride can cause a condition called hand-foot syndrome. This may present as redness, swelling, tingling, pain, or peeling of the palms of the hands and soles of the feet. Keeping hands and feet cool, moisturised, and protected from friction can help. Report early signs of hand-foot syndrome promptly, as dose adjustments or supportive care may be needed.

Mouth ulcers and soreness can also occur with pegylated liposomal doxorubicin hydrochloride. Good oral hygiene is important. Use a soft toothbrush, avoid alcohol-based mouthwashes, and report any mouth pain, ulcers, or difficulty eating or drinking while receiving pegylated liposomal doxorubicin hydrochloride.

Pegylated liposomal doxorubicin hydrochloride can suppress the bone marrow. This means it can lower white blood cells, red blood cells, and platelets. Low white blood cells increase the risk of infection. You must seek urgent medical attention if you develop a fever of 38 degrees Celsius or higher, chills, sore throat, cough, or feel suddenly unwell while on pegylated liposomal doxorubicin hydrochloride.

Low red blood cells can cause tiredness, weakness, dizziness, or shortness of breath. Low platelets increase the risk of bruising or bleeding. Report nosebleeds, bleeding gums, blood in urine or stools, black stools, or unusual bruising during treatment with pegylated liposomal doxorubicin hydrochloride.

Regular blood tests are essential while receiving pegylated liposomal doxorubicin hydrochloride. These tests help your healthcare team decide when it is safe to give the next dose and whether any dose adjustments are required.

Pegylated liposomal doxorubicin hydrochloride can still affect the heart, although the risk is lower than with standard doxorubicin. Your heart function may be checked before and during treatment. Inform your healthcare team if you develop shortness of breath, swelling of the ankles, rapid weight gain, chest discomfort, or unusual fatigue while on pegylated liposomal doxorubicin hydrochloride.

Other common side effects of pegylated liposomal doxorubicin hydrochloride include nausea, vomiting, loss of appetite, fatigue, weakness, constipation or diarrhoea, and temporary hair thinning. Anti-nausea medicines are often given to help manage stomach upset. Hair loss is usually less severe with pegylated liposomal doxorubicin hydrochloride compared to standard doxorubicin.

Pegylated liposomal doxorubicin hydrochloride may cause your urine to appear reddish for a day or two after treatment. This is expected and harmless and is due to the colour of the medicine, not blood.

Pegylated liposomal doxorubicin hydrochloride can damage tissue if it leaks outside the vein during infusion. Tell the nurse immediately if you feel pain, burning, stinging, or swelling at the infusion site.

Pregnancy must be avoided during treatment with pegylated liposomal doxorubicin hydrochloride, as it can harm an unborn baby. Effective contraception is required during treatment and for the period advised after treatment ends. Breastfeeding must not be continued while receiving pegylated liposomal doxorubicin hydrochloride.

I want to acknowledge that receiving chemotherapy such as pegylated liposomal doxorubicin hydrochloride can be physically and emotionally demanding. Feeling tired, anxious, or overwhelmed is completely understandable. Your healthcare team is there to support you, and you should always feel comfortable raising concerns or asking questions.

In summary, pegylated liposomal doxorubicin hydrochloride is a specialised form of doxorubicin chemotherapy designed to treat cancer effectively while reducing some side effects. Safe and effective use of pegylated liposomal doxorubicin hydrochloride depends on regular blood monitoring, early reporting of infection or skin symptoms, awareness of infusion reactions, and attending all scheduled treatments and reviews. If you have any questions or concerns at any stage of treatment with pegylated liposomal doxorubicin hydrochloride, please raise them promptly so you can be supported and treated safely.